Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

Update on the use of immunoglobulin in human disease: A review of evidence

(2017) Elena E. Perez et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy

(2017) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

(2017) Andrew Davies et al.   Lancet Haematology

P259 Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IGHY)

(2016) P. Gruenemeier et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

P255 Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters

(2016) P. Gruenemeier et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

(2016) M. Borte et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

(2016) Hosein Shabaninejad et al.   Expert Review of Clinical Immunology

Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability

(2016) Richard L Wasserman et al.   Immunotherapy

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

(2016) Daniel Suez et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

(2016) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

(2015) Sanna Rosengren et al.   AAPS Journal

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies

(2015) Aziz Bousfiha et al.   JOURNAL OF CLINICAL IMMUNOLOGY

The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies

(2015) Mary Lucas et al.   Journal of Allergy and Clinical Immunology-In Practice

Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery

(2014) Vicki Modell et al.   IMMUNOLOGIC RESEARCH

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

(2014) Richard L Wasserman   Immunotherapy

Prevalence and Morbidity of Primary Immunodeficiency Diseases, United States 2001–2007

(2014) Lisa Kobrynski et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment

(2014) Teresa Espanol et al.   Patient Preference and Adherence

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

(2013) O Shpilberg et al.   BRITISH JOURNAL OF CANCER

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

(2012) Richard L. Wasserman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

(2012) Richard L. Wasserman   JOURNAL OF CLINICAL IMMUNOLOGY

Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought

(2012) Ahmed Aziz Bousfiha et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Functional Characterization of Double-knockout Mouse Sperm Lacking SPAM1 and ACR or SPAM1 and PRSS21 in Fertilization

(2012) Chong ZHOU et al.   JOURNAL OF REPRODUCTION AND DEVELOPMENT

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

(2012) David W. Kang et al.   Drug Delivery and Translational Research

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

(2011) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

(2011) Melvin Berger   JOURNAL OF CLINICAL IMMUNOLOGY

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

(2010) Jordan S. Orange et al.   CLINICAL IMMUNOLOGY

Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models

(2010) C. B. Thompson et al.   MOLECULAR CANCER THERAPEUTICS

Subcutaneous immunoglobulin: opportunities and outlook

(2009) S. Misbah et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies

(2009) Pierre L. Yong et al.   CLINICAL IMMUNOLOGY

Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection

(2008) Vincent R. Bonagura et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY